BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
Litum Brings High-Precision Location Visibility to Zone 1 and Zone 2 Hazardous Environments15.6.2026 09:00:00 CEST | Press release
Combining ATEX Zone 1 and Zone 2 suitability with high-precision location capability, the ATEX Gateway and ATEX Dualis Tag set a new benchmark for intrinsically safe RTLS in hazardous industrial environments BOSTON, MA / ACCESS Newswire / June 15, 2026 / Litum, a global leader in real-time location systems, today announced the ATEX Family: a purpose-built hardware suite comprising the ATEX Gateway and ATEX Dualis Tag. Compliant with both Zone 1 and Zone 2 hazardous areas, the ATEX Family is designed to deliver sub-meter location accuracy and better visibility in environments where standard connected devices cannot be safely deployed. The launch marks a significant step forward for industrial organizations that need to track critical assets, equipment, tools, materials, and people in environments where explosive gases, vapors, or combustible dust may be present. By combining intrinsically safe design with Ultra-Wideband (UWB) and Bluetooth Low Energy (BLE) location capability, Litum ena
GA-ASI and INTEC Group Sign MOU at ILA Berlin11.6.2026 17:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / June 11, 2026 / Today at the ILA Berlin Air Show, General Atomics Aeronautical Systems, Inc. (GA-ASI) and the INTEC Group signed a Memorandum of Understanding (MoU) for INTEC to support the architecture and integration of mission systems, entry into service and logistic support services for GA-ASI's Gambit Series of Collaborative Combat Aircraft (CCA). The work is intended to provide sovereign capabilities to meet the growing interest in CCA in Germany. The MoU was signed by GA-ASI CEO Linden Blue and INTEC Group CEO Christoph Otten. GA-ASI's flight-proven Gambit CCA provides a common platform for air-to-air, air-to-ground and electronic warfare missions. Gambit is an uncrewed combat jet optimized for attack roles such as electronic warfare, Suppression of Enemy Air Defenses (SEAD), Destruction of Enemy Air Defenses (DEAD) and stand-off precision strike, making it a versatile option for evolving security needs. GA-ASI is currently flight testing the YFQ-4
U.S. Polo Assn. Palm Beaches Marathon Celebrates America's 250th, Adds $17,000 in Prize Money as it Returns December 12-13, 202611.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 11, 2026 / The 2026 U.S. Polo Assn. Palm Beaches Marathon, a celebration of America's 250th, will introduce prize money for its top Marathon runners for the first time when the race returns to the streets of West Palm Beach on December 12-13, 2026, a move that will attract elite runners worldwide and elevate the status of Palm Beach County's most treasured road test. The introduction of $17,000 in prize money is the next strategic step for elevating this racing event that has experienced record growth in recent years. The men's and women's winners of the Marathon race will each receive $5,000, second-place finishers will receive $2,500, and third place will be worth $1,000. The winners' share of the purse is the largest in the state of Florida. In celebration of America's 250th, the 2026 U.S. Polo Assn. Palm Beaches Marathon Logo has been re-designed in stunning brushstrokes of red, white and blue to accompany the brand's iconic double horse
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom